Log in to your IBTimes Account

close
ID
Password
  • Set your IBTimes.com Edition

CV Therapeutics Shares Fall on Downgrade



By Joseph Major
28 March 2007 @ 06:35 pm ET

Shares of CV Therapeutics Inc.(Nasdaq: CVTX) fell on Wednesday, after Citigroup downgraded the firm.

Related Topic

Get stories by e-mail on this topic.

  • cv therapeutics shares | RSS
E-mail:

CV Therapeutics fell 67 cents,the or 8.42 percent, to $7.29 after the rating on stock was cut to 'sell' from 'hold.'

Citigroup analyst Dr. Yaron Werber lowered the firm's price target to $6 from $15, stating that he saw diminished market potential for Ranexa, a drug already approved to treat chronic angina. A study involving the drug this week showed that Ranexa did not meet its goals.

He also noted that the company has high operating costs and is in need of additional financing. He stated that finding the funds could be difficult based on the Ranexa results and the current amount of debt at the firm.

This article is copyrighted by International Business Times.

    Click!
  • Rate this article:

Comments

Post Your Comment

*Name


advertisement
More Global Markets
Whereas gold has forged ahead to new highs in recent weeks, silver has got bogged down working off overhanging supply, which is the price it is paying fo...
Last week gold's major new uptrend became established when following a successful test of support at the breakout point it advanced to new highs, indiffe...
An avowed Keynesian, Equities and Economics Report writer Victor Gonçalves braces against the economic gale-force headwinds that threaten to whip gold's ...

advertisement
Advertisement
POS Magnetic Card Readers

Online distributor for point of sale equipment, TYSSO and Pegasus.

 
IBTimes.com Web
Partners
International Business Times© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives